Search results
Apr 24, 2020 · Janet Woodcock, the FDA's top drug regulator, spoke with STAT about the agency's decision to approve the emergency use of hydroxychloroquine.
May 22, 2020 · The following day, the director of the Center for Drug Evaluation and Research, Dr. Janet Woodcock, called Bright and strongly recommended that BARDA submit an application for an EUA instead of an ...
May 5, 2020 · Emails quoted in Bright’s complaint suggest that Janet Woodcock, the longtime head of Food and Drug Administration’s drug review department, was among those who supported Bright’s warnings ...
An analysis done by Janet Woodcock, MD, who headed the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA) and had served as the therapeutics lead for Operation Warp Speed (and is currently the agency’s acting commissioner) found that more than 90% of the clinical trials underway that evaluated different ...
- Scott Gottlieb
- 2021
May 14, 2020 · In his whistleblower complaint, Bright said he worked with Janet Woodcock, a top FDA official, to draft an Emergency Use Authorization request, which the FDA signed off on March 29. Under the EUA, the FDA specified hydroxychloroquine use be limited to treating patients hospitalized with COVID-19 who are unable to join a clinical trial.
Jun 16, 2020 · Dr. Janet Woodcock, who heads the F.D.A.’s Center for Drug Evaluation and Research, ultimately decided to issue the emergency use authorization, but only for hospitalized patients who could not ...
Janet Woodcock 1; Kevin Bugin. US Food and Drug Administration, Silver Spring, MD, USA. ... This shift was probably driven in part by the finding of lack of efficacy for hydroxychloroquine and ...
